VRTX · US market

Vertex Pharmaceuticals Inc

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$128.44bnFinancials dated 30 June 2026Price dated 1 October 2026

Core valuation

Trailing P/E29.16×
Latest-quarter run-rate P/E29.20×
Trailing P/S10.20×
Latest-quarter run-rate P/S9.63×

Calculation inputs

Trailing earnings
US$4.41bn
Latest-quarter run-rate earnings
US$4.40bn
Latest fiscal-year earnings
US$3.95bn
Trailing revenue
US$12.59bn
Latest-quarter run-rate revenue
US$13.34bn
Latest fiscal-year revenue
US$12.00bn

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 June 2026. Informational research, not investment advice.